Recent Advances in Perioperative Immunotherapies in Lung Cancer

• Published in: Biomolecules (Basel, Switzerland) Vol. 13; no. 9; p. 1377
• Main Authors: Fukuda, Shota, Suda, Kenichi, Hamada, Akira, Tsutani, Yasuhiro
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.09.2023; MDPI
• Subjects: adjuvant treatment; Antigens; Apoptosis; biomarker; Biomarkers; Cancer immunotherapy; Cancer therapies; Care and treatment; Cell death; Chemotherapy; Clinical trials; Cytotoxicity; Forecasts and trends; ICI combination therapies; Immune checkpoint; Immunosuppressive agents; Immunotherapy; Kinases; Ligands; Lung cancer; Lymphocytes; Metastasis; Methods; neoadjuvant treatment; non-small cell lung cancer (NSCLC); Non-small cell lung carcinoma; Patients; PD-1 protein; PD-L1 protein; Preoperative care; Review; Small cell lung carcinoma; stage migration; T cell receptors; Japan
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom13091377

Several clinical trials have been revolutionizing the perioperative treatment of early-stage non-small cell lung cancer (NSCLC). Many of these clinical trials involve cancer immunotherapies with antibody drugs that block the inhibitory immune checkpoints programmed death 1 (PD-1) and its ligand PD-L1. While these new treatments are expected to improve the treatment outcome of NSCLC patients after pulmonary resection, several major clinical questions remain, including the appropriate timing of immunotherapy (neoadjuvant, adjuvant, or both) and the identification of patients who should be treated with neoadjuvant and/or adjuvant immunotherapies, because some early-stage NSCLC patients are cured by surgical resection alone. In addition, immunotherapy may induce immune-related adverse events that will require permanent treatment in some patients. Based on this fact as well, it is desirable to select appropriate patients for neoadjuvant/adjuvant immunotherapies. So far, data from several important trials have been published, with findings demonstrating the efficacy of adjuvant atezolizumab (IMpower010 trial), neoadjuvant nivolumab plus platinum-doublet chemotherapy (CheckMate816 trial), and several perioperative (neoadjuvant plus adjuvant) immunotherapies (AEGEAN, KEYNOTE-671, NADIM II, and Neotorch trials). In addition to these key trials, numerous clinical trials have reported a wealth of data, although most of the above clinical questions have not been completely answered yet. Because there are so many ongoing clinical trials in this field, a comprehensive understanding of the results and/or contents of these trials is necessary to explore answers to the clinical questions above as well as to plan a new clinical trial. In this review, we comprehensively summarize the recent data obtained from clinical trials addressing such questions.